Encapsulation of Mesenchymal Stem Cells: Dissecting the Underlying Mechanism of Mesenchymal Stem Cell Transplantation Therapy.

brain-derived neurotrophic factor ciliary neurotrophic factor depression fibroblast growth factor-2 mesenchymal stem cells transplantation vascular endothelial growth factor

Journal

Neuroscience insights
ISSN: 2633-1055
Titre abrégé: Neurosci Insights
Pays: United States
ID NLM: 101760670

Informations de publication

Date de publication:
2020
Historique:
received: 22 08 2020
accepted: 26 08 2020
entrez: 22 10 2020
pubmed: 23 10 2020
medline: 23 10 2020
Statut: epublish

Résumé

Mesenchymal stem cells (MSCs) are widely considered good candidates for cell transplantation therapy. Various central nervous system disorders have been suggested as suitable targets for MSC transplantation therapy. In this context, a great deal of basic and clinical research has been conducted to explore its clinical uses. Although depression is one of the most common diseases in the world, the response rate to the currently available treatment is insufficient and new treatments are much needed. Despite the fact that MSC transplantation therapy has the potential to elicit an antidepressant effect, few studies have been conducted on this topic to date and the underlying mechanism remains poorly understood. To address the development of a new treatment for depression, we evaluated the effect of MSCs using the encapsulation technique and Wistar-Kyoto rats. Encapsulation enables dissection of the complicated underlying mechanism of MSC transplantation therapy. Wistar-Kyoto rats that exhibit treatment-resistant depressive-like behaviors allow us to compare the effect of MSCs with that of conventional antidepressant treatment. In this commentary, we briefly summarize our recent published results and discuss future research prospects.

Identifiants

pubmed: 33089215
doi: 10.1177/2633105520959064
pii: 10.1177_2633105520959064
pmc: PMC7543158
doi:

Types de publication

Journal Article Comment

Langues

eng

Pagination

2633105520959064

Commentaires et corrections

Type : CommentOn

Informations de copyright

© The Author(s) 2020.

Déclaration de conflit d'intérêts

Declaration of conflicting Interests:The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Références

Stem Cells. 2008 Oct;26(10):2654-63
pubmed: 18687995
J Neurosci. 2000 Dec 15;20(24):9104-10
pubmed: 11124987
Mol Psychiatry. 2020 Jun;25(6):1202-1214
pubmed: 30108315
CNS Neurosci Ther. 2020 Jun;26(6):595-602
pubmed: 31622035
Behav Brain Res. 2017 Jun 30;329:148-156
pubmed: 28465137
Psychoneuroendocrinology. 2002 Apr;27(3):303-18
pubmed: 11818168
Stem Cells Transl Med. 2020 Jun 23;:
pubmed: 32573961
Stem Cell Rev Rep. 2019 Dec;15(6):814-826
pubmed: 31515658
Rev Neurosci. 2019 Nov 26;30(8):839-855
pubmed: 31203262
Neuroscience. 2002;115(1):229-42
pubmed: 12401336
Prog Neuropsychopharmacol Biol Psychiatry. 2014 Oct 3;54:170-8
pubmed: 24871798
Drug Deliv. 2016 Nov;23(9):3520-3528
pubmed: 27278330
Prog Neuropsychopharmacol Biol Psychiatry. 2010 Feb 1;34(1):62-9
pubmed: 19800382
Mol Psychiatry. 2010 Dec;15(12):1164-75
pubmed: 19859069
J Neurotrauma. 2012 Nov 20;29(17):2647-59
pubmed: 23016562

Auteurs

Kyohei Kin (K)

Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

Takao Yasuhara (T)

Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

Isao Date (I)

Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

Classifications MeSH